Skip to content

Empiric Diagnosis and Treatment of Gastroesophageal Reflux in Infants Born Extremely Preterm and Associations with Growth and Development.

Nov 2026 · Jornal de Pediatria · pp. 115387 · 0 citations · 27 references
Medicine

Abstract

Objective

To examine the association of anti-reflux medication (ARM) for presumed gastroesophageal reflux (GER) with 2-year growth and development outcomes in infants born extremely preterm . STUDY

Design

Cohort study of infants <27 weeks' gestation born between July 1, 2012, and December 31, 2019, who survived to 22-26-months corrected age follow-up. Infants were compared based on ARM use at the time of discharge. Outcomes of interest included z-scores for weight, length, and head circumference, and moderate-severe neurodevelopmental impairment (NDI) at follow-up. Analysis was completed using linear mixed and robust Poisson models, adjusting for ARM at discharge and other covariates. Analysis also compared infants who stopped or started ARMs prior to follow-up.

Results

Of 3,483 included infants, 508 (15%) were discharged on ARM. Use at discharge decreased from 18% to 11% during the years studied (P=0.01). At follow-up, 9% of infants in the cohort were on ARM. When adjusted, there was an association of ARM with lower weight z-score and moderate/severe NDI at follow-up (absolute mean -0.18 [95% CI 0.35,-0.01]) and relative risk 1.16 [95% 1.01, 1.35], respectively). NDI risk differed between groups, highest for infants discharged on ARM who did not stop before follow-up (P=0.004).

Conclusions

From 2012-2019, the percent of infants discharged on reflux medications decreased. Accounting for comorbidities, ARM at discharge may be associated with poor growth and moderate/severe NDI at follow-up; however, confounding by indication cannot be excluded.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.